Finch Therapeutics Group Inc
Change company Symbol lookup
Select an option...
FNCH Finch Therapeutics Group Inc
BFS Saul Centers Inc
ABB Abb Ltd
BURL Burlington Stores Inc
TNEN True North Energy Corp
H Hyatt Hotels Corp
ACEL Accel Entertainment Inc
USLM United States Lime & Minerals Inc
BWEN Broadwind Inc
EQIX Equinix Inc

Health Care : Biotechnology | Small Cap Growth
Company profile

Finch Therapeutics Group, Inc. is a clinical-stage microbiome therapeutics company. It is engaged in leveraging its Human-First Discovery platform to develop a class of orally administered biological drugs. Its Human-First Discovery platform uses reverse translation to identify diseases of dysbiosis and to design microbiome therapeutics that address them. Its lead product candidate, CP101, is an orally administered complete microbiome therapeutic in development for the prevention of recurrent Clostridioides difficile infection (CDI). CP101, consists of a microbial community harvested from rigorously screened healthy donors that is lyophilized and formulated in orally administered capsules designed to release at the appropriate location in the gastrointestinal tract. CP101 is designed to deliver a complete microbiome, addressing the community-level dysbiosis that characterizes CDI. Its product pipeline includes FIN-211, TAK-524, and FIN-525, as well as consortia product candidates.

Closing Price
Day's Change
0.13 (5.26%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

The risk of loss in trading futures can be substantial. Clients must consider all relevant risk factors, including their own personal financial situation, before trading. Margin and level 2 options approval or higher is required. Not all account owners will qualify.

Dividends are converted to USD using the current rate of exchange at the end of the business day on the day the dividend went EX. Earnings are converted to USD using the current rate of exchange at the end of the business day on the day earnings were announced.

Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.